What's Going On With Summit Therapeutics Stock On Friday?

Summit Therapeutics Inc SMMT stock is trading lower on Friday.On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease ...